氘可来昔替尼片效果如何？

Deuterated colexitinib tablets developed by Bristol-Myers Squibb (BMS), R&D code: BMS-986165, trade name Sotyktu, is the world's first and currently only drug approved by the U.S. FDA. An oral, selective TYK2 inhibitor was approved on September 9, 2022, for the treatment of adult patients with moderate to severe plaque psoriasis who are suitable for systemic treatment or phototherapy. The approved dosage form is an oral tablet with a strength of 6. mg/tablet. On September 26, 2022, Deuterated Colexitinib Tablets were approved by PMDA in Japan for the treatment of plaque psoriasis, systemic pustular psoriasis and erythrodermic psoriasis. So, how effective is Deuterated Colexitinib Tablets?

Deuterated colexitinib tablets effects

After completing 52 weeks of POETYK PSO-1 and POETYK PSO-2, patients can participate in the ongoing POETYK PSO-LTE trial (NCT04036435) and continue to receive deuterated colexitinib tablets (6 mg once/d) in an open-label format [1].

A total of 1,221 patients participated in this long-term extension trial and received at least one treatment with deuterated colexitinib tablets. From Week 0 to Week 60 of PSO-LTE, patients who had already taken deuterated colexitinib tablets at Week 0 continued to improve (PASI 75 from 70.8% to 79.4% and PASI 90 from 43.6% to 50.7%). Patients who switched from apremilast to colexitinib at week 0 also experienced clinical improvement (PASI 75 from 73.8% to 87.1% and PASI 90 from 40.0% to 62.9%).

The overall safety results of two-year treatment with colexitinib announced this time are consistent with the previously reported results of the key phase III POETYK PSO-1 and POETYK PSO-2 studies. Adverse events are still mainly mild or moderate.

Deuterated colexitinib tablets are effective

The results of two clinical phase III trials and multiple clinical phase II trials that have been completed so far have shown that deuterated colexitinib tablets have a significant therapeutic effect in the treatment of adult patients with moderate to severe plaque psoriasis, and the two-year results of the long-term extension trial (POETYK PSO-LTE) confirmed that deuterated colexitinib tablets are well tolerated and safe for the treatment of moderate to severe plaque psoriasis.

References

[1] Yu Yanping, Chen Cheng, Fan Zhaoze, Su Lilin, Huang Lu. New selective TYK2 inhibitor Deucravacitinib for the treatment of psoriasis [J/OL ].Chinese Journal of Dermatology and Venereology:1-11[2023-06-06].DOI:10.13735/j.cjdv.1001-7089.202211112.

Recommended related articles: